Literature DB >> 24179172

With complements from ANCA mice.

Ralph Kettritz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24179172      PMCID： PMC3904575          DOI： 10.1681/ASN.2013101043

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  12 in total

1.  Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies.

Authors:  Hong Xiao; Adrian Schreiber; Peter Heeringa; Ronald J Falk; J Charles Jennette
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 2.  How anti-neutrophil cytoplasmic autoantibodies activate neutrophils.

Authors:  R Kettritz
Journal:  Clin Exp Immunol       Date:  2012-09       Impact factor: 4.330

3.  Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.

Authors:  Hong Xiao; Peter Heeringa; Peiqi Hu; Zhi Liu; Minglang Zhao; Yasuaki Aratani; Nobuyo Maeda; Ronald J Falk; J Charles Jennette
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

4.  Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice.

Authors:  D Huugen; A van Esch; H Xiao; C J Peutz-Kootstra; W A Buurman; J W Cohen Tervaert; J C Jennette; P Heeringa
Journal:  Kidney Int       Date:  2007-02-14       Impact factor: 10.612

5.  C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis.

Authors:  Adrian Schreiber; Hong Xiao; J Charles Jennette; Wolfgang Schneider; Friedrich C Luft; Ralph Kettritz
Journal:  J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 10.121

Review 6.  The complement system in systemic autoimmune disease.

Authors:  Min Chen; Mohamed R Daha; Cees G M Kallenberg
Journal:  J Autoimmun       Date:  2009-12-11       Impact factor: 7.094

7.  Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Shen-Ju Gou; Jun Yuan; Min Chen; Feng Yu; Ming-Hui Zhao
Journal:  Kidney Int       Date:  2012-08-22       Impact factor: 10.612

8.  Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis.

Authors:  Min Chen; Guang-Qun Xing; Feng Yu; Gang Liu; Ming-Hui Zhao
Journal:  Nephrol Dial Transplant       Date:  2008-10-21       Impact factor: 5.992

9.  Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis.

Authors:  F J van der Woude; N Rasmussen; S Lobatto; A Wiik; H Permin; L A van Es; M van der Giessen; G K van der Hem; T H The
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

10.  C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Authors:  Jun Yuan; Shen-Ju Gou; Jing Huang; Jian Hao; Min Chen; Ming-Hui Zhao
Journal:  Arthritis Res Ther       Date:  2012-06-12       Impact factor: 5.156
View more
  8 in total

1.  Incidence and risk factors of venous thromboembolism in ANCA-associated vasculitis: a metaanalysis and metaregression.

Authors:  Panupong Hansrivijit; Angkawipa Trongtorsak; Kinjal P Gadhiya; Kriti Lnu; Christina T Dimech; Charat Thongprayoon; Wisit Cheungpasitporn; Stewart H Lecker
Journal:  Clin Rheumatol       Date:  2021-01-15       Impact factor: 2.980

2.  Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

Authors:  David R W Jayne; Annette N Bruchfeld; Lorraine Harper; Matthias Schaier; Michael C Venning; Patrick Hamilton; Volker Burst; Franziska Grundmann; Michel Jadoul; István Szombati; Vladimír Tesař; Mårten Segelmark; Antonia Potarca; Thomas J Schall; Pirow Bekker
Journal:  J Am Soc Nephrol       Date:  2017-04-11       Impact factor: 10.121

Review 3.  Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives.

Authors:  Lucio Manenti; Maria Letizia Urban; Federica Maritati; Maricla Galetti; Augusto Vaglio
Journal:  Intern Emerg Med       Date:  2017-02-13       Impact factor: 3.397

Review 4.  The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy.

Authors:  G Trivioli; A Vaglio
Journal:  Clin Exp Immunol       Date:  2020-10-05       Impact factor: 4.330

5.  Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes among Patients with ANCA-Associated Renal Vasculitis.

Authors:  Lucio Manenti; Augusto Vaglio; Elisa Gnappi; Umberto Maggiore; Landino Allegri; Marco Allinovi; Maria L Urban; Marco Delsante; Maricla Galetti; Maria Nicastro; Francesco P Pilato; Carlo Buzio
Journal:  Clin J Am Soc Nephrol       Date:  2015-11-05       Impact factor: 8.237

Review 6.  Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis.

Authors:  Marc Hilhorst; Pieter van Paassen; Jan Willem Cohen Tervaert
Journal:  J Am Soc Nephrol       Date:  2015-05-08       Impact factor: 10.121

7.  Identification of differentially expressed genes and pathways in kidney of ANCA-associated vasculitis by integrated bioinformatics analysis.

Authors:  Xu Deng; Junying Gao; Fei Zhao
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

8.  Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial.

Authors:  Peter A Merkel; David R Jayne; Chao Wang; Jan Hillson; Pirow Bekker
Journal:  JMIR Res Protoc       Date:  2020-04-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.